Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7284755 |
Synonyms | |
Therapy Description |
RO7284755 consists of an alternate form of the cytokine IL-2 (IL-2v) fused to an antibody against PD-1, which may inhibit PD-1-mediated immune suppression and lead to activation of anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7284755 | RO-7284755|RO 7284755|PD1-IL2v | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | RO7284755 consists of an alternate form of the cytokine IL-2 (IL-2v) fused to an antibody against PD-1, which may inhibit PD-1-mediated immune suppression and lead to activation of anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04303858 | Phase I | Atezolizumab + RO7284755 RO7284755 | A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | POL | NLD | ESP | DNK | CAN | BEL | 0 |